# reload+after+2024-01-21 13:43:29.877601
address1§18706 North Creek Parkway
address2§Suite 104
city§Bothell
state§WA
zip§98011
country§United States
phone§425 620 8501
website§https://www.athira.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
fullTimeEmployees§63
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mark J. Litton M.B.A., Ph.D.', 'age': 55, 'title': 'President, CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 777147, 'exercisedValue': 0, 'unexercisedValue': 91801}, {'maxAge': 1, 'name': 'Ms. Rachel P. Lenington M.B.A.', 'age': 50, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 578005, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Andrew W. Gengos', 'age': 59, 'title': 'CFO & Chief Business Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Kevin  Church Ph.D.', 'age': 38, 'title': 'Chief Scientific Officer', 'yearBorn': 1985, 'fiscalYear': 2022, 'totalPay': 123666, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Julie  Rathbun', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark F. Worthington J.D.', 'age': 57, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 503828, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Samantha  Willing', 'title': 'Executive Vice President of People', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§5
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§2.788
currency§USD
dateShortInterest§1702598400
forwardEps§-2.99
exchange§NMS
quoteType§EQUITY
shortName§Athira Pharma, Inc.
longName§Athira Pharma, Inc.
firstTradeDateEpochUtc§1600435800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bcfbfaea-5231-3987-ba3c-d263d037ec62
gmtOffSetMilliseconds§-18000000
targetHighPrice§19.0
targetLowPrice§3.0
targetMeanPrice§7.33
targetMedianPrice§4.5
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§6.042
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
